# CSRA's DynPort Vaccine Company wins $159M NIAID contract

CSRA Inc.'s subsidiary DynPort Vaccine Company LLC received a multiple-award IDIQ contract valued up to $159 million from the National Institute of Allergy and Infectious Diseases to manage medical product development initiatives.

- Type: Contract
- Announced: 2016-12-27
- Where: United States
- Value: $159.0M
- Status: announced
- Products: medical products, vaccines, therapies
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [CSRA](https://endata.com/companies/21013.md)
- [DynPort Vaccine Company](https://endata.com/companies/21014.md)
- [National Institute of Allergy and Infectious Diseases](https://endata.com/companies/21015.md) (customer)

## Sources

- [prnewswire.com](https://www.prnewswire.com/news-releases/csras-dynport-vaccine-company-to-help-advance-medical-products-for-the-national-institute-of-allergy-and-infectious-diseases-300383366.html), 2016-12-27: "DVC has been successfully conducting product development for government agencies for nearly 20 years."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.